ACADIA Historical Income Statement
| ACAD Stock | USD 16.32 0.03 0.18% |
Historical analysis of ACADIA Pharmaceuticals income statement accounts such as Selling General Administrative of 412.7 M, Total Revenue of 762.8 M or Gross Profit of 714.7 M can show how well ACADIA Pharmaceuticals performed in making a profits. Evaluating ACADIA Pharmaceuticals income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of ACADIA Pharmaceuticals's future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining ACADIA Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether ACADIA Pharmaceuticals is a good buy for the upcoming year.
ACADIA |
About ACADIA Income Statement Analysis
ACADIA Pharmaceuticals Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to ACADIA Pharmaceuticals shareholders. The income statement also shows ACADIA investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
ACADIA Pharmaceuticals Income Statement Chart
Add Fundamental
Interest Expense
The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.Total Revenue
Total revenue comprises all receipts ACADIA Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of ACADIA Pharmaceuticals. It is also known as ACADIA Pharmaceuticals overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from ACADIA Pharmaceuticals' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into ACADIA Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.At present, ACADIA Pharmaceuticals' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Total Revenue is expected to grow to about 762.8 M, whereas EBIT is forecasted to decline to (77 M).
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 19.1M | 10.2M | 45.7M | 25.4M | Depreciation And Amortization | 3.3M | 2.0M | 5.6M | 5.8M |
ACADIA Pharmaceuticals income statement Correlations
Click cells to compare fundamentals
ACADIA Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ACADIA Pharmaceuticals income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 14.9M | 8.5M | 6.3M | 6.6M | 7.6M | 8.0M | |
| Selling General Administrative | 325.6M | 388.7M | 396.0M | 369.1M | 393.1M | 412.7M | |
| Total Revenue | 339.1M | 441.8M | 484.1M | 517.2M | 726.4M | 762.8M | |
| Gross Profit | 319.5M | 421.2M | 465.0M | 507.1M | 680.7M | 714.7M | |
| Other Operating Expenses | 585.6M | 728.3M | 654.6M | 740.8M | 799.8M | 839.8M | |
| Operating Income | (246.5M) | (286.6M) | (170.4M) | (223.6M) | (73.4M) | (77.0M) | |
| Ebit | (246.5M) | (286.6M) | (170.4M) | (223.6M) | (73.4M) | (77.0M) | |
| Research Development | 240.4M | 319.1M | 239.4M | 361.6M | 351.6M | 369.2M | |
| Ebitda | (243.8M) | (283.7M) | (167.1M) | (221.6M) | (67.8M) | (71.2M) | |
| Total Operating Expenses | 566.0M | 707.8M | 635.4M | 730.7M | 754.1M | 791.8M | |
| Net Income | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (61.3M) | (64.4M) | |
| Income Tax Expense | 876K | 611K | 351K | 2.5M | 10.3M | 10.8M | |
| Depreciation And Amortization | 2.8M | 2.9M | 3.3M | 2.0M | 5.6M | 5.8M | |
| Cost Of Revenue | 19.6M | 20.6M | 19.1M | 10.2M | 45.7M | 25.4M | |
| Income Before Tax | (234.4M) | (281.0M) | (167.5M) | (213.4M) | (51.0M) | (53.6M) | |
| Total Other Income Expense Net | 12.2M | 5.6M | 2.9M | 10.2M | 22.3M | 23.5M | |
| Net Income Applicable To Common Shares | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (194.4M) | (204.1M) | |
| Net Income From Continuing Ops | (235.3M) | (281.6M) | (167.9M) | (216.0M) | (61.3M) | (64.4M) | |
| Tax Provision | 876K | 611K | 351K | 2.5M | 10.3M | 10.8M | |
| Interest Income | 5.3M | 11.2M | 6.6M | 591K | 17.2M | 18.1M | |
| Net Interest Income | 5.3M | 11.2M | 6.6M | 591K | 17.2M | 18.1M | |
| Selling And Marketing Expenses | 38.3M | 51.1M | 41.8M | 5.5M | 9.4M | 8.9M | |
| Reconciled Depreciation | 2.8M | 2.9M | 3.3M | 2.0M | 5.6M | 3.5M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether ACADIA Pharmaceuticals is a strong investment it is important to analyze ACADIA Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact ACADIA Pharmaceuticals' future performance. For an informed investment choice regarding ACADIA Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ACADIA Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade ACADIA Stock refer to our How to Trade ACADIA Stock guide.You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ACADIA Pharmaceuticals. If investors know ACADIA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ACADIA Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 28.347 | Earnings Share 0.78 | Revenue Per Share 5.622 | Quarterly Revenue Growth 0.183 | Return On Assets 0.0872 |
The market value of ACADIA Pharmaceuticals is measured differently than its book value, which is the value of ACADIA that is recorded on the company's balance sheet. Investors also form their own opinion of ACADIA Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ACADIA Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ACADIA Pharmaceuticals' market value can be influenced by many factors that don't directly affect ACADIA Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ACADIA Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ACADIA Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ACADIA Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.